泌尿器科領域におけるNORFLOXACIN (BACCIDAL(R))の使用経験

Abstract

1)女子急性単純性膀胱炎40例, 複雑性尿路感染症10例の計50例にノルフロキサシン投与による効果判定をおこなった.2)女子急性単純性膀胱炎群では32株, 複雑性尿路感染症群では10株の菌が分離され, ノルフロキサシンの3濃度ディスク法での感受性率は, 前者で平均97%, 後者で平均89%であった.3) UTI薬効評価基準による効果判定は女子急性単純性膀胱炎群で97%, 複雑性尿路感染症候群は60%の有効率であった.4)副作用で薬剤投与と関係あると思われたものは50例中4例(8.0%)であり, その種類は悪心, 腹部膨満感, 頭痛であった.5)臨床検査値の異常変動で薬剤投与と関係あると思われたものは, 24例中1例(4%)であった

The clinical effectiveness of a new synthetic pyridoncarboxylic acid derivative, norfloxacin (NFLX: Baccidal) was studied in the urological field. NFLX was given clinically to 50 patients with urogenital tract infections; 40 cases were acute simple cystitis and 10 cases were complicated UTI satisfied the criteria of the UTI committee. Thirty two bacterial strains were isolated from the group of acute simple cystitis and 10 bacterial strains were isolated from the group of complicated UTI. Susceptibility of NFLX by the method of distribution and disk sensitivity was 97% in the former group and 89% in the latter group. The overall clinical efficacy rate estimated by the criteria of the UTI committee in 32 cases with acute simple cystitis was 97% and in 10 cases with complicated UTI was 60%. The incidence of side effect was 8.0% (4/50). All of these side effects which were nausea, abdominal fullness and headache may be attributable to the administration of NFLX. No abnormal laboratory findings were observed except for elevation in GOT and GPT values in 1 case (4.0%), which returned to normal after NFLX treatment. Therefore NFLX is suggested to be a clinically useful and safe drug in the treatment of UTI.